These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21803876)

  • 1. Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer.
    Uehara K; Ishiguro S; Sakamoto E; Maeda A; Inoue M; Tojima Y; Kobayashi S; Omiya N; Ishizuka N; Nakao A; Goto H; Nagino M
    Jpn J Clin Oncol; 2011 Aug; 41(8):1041-4. PubMed ID: 21803876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
    Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective feasibility study to evaluate neoadjuvant-synchronous S-1 + RT for locally advanced rectal cancer: a multicenter phase II trial (UMIN ID: 03396).
    Inomata M; Akagi T; Nakajima K; Etoh T; Shiraishi N; Tahara K; Matsumoto T; Kinoshita T; Fujii K; Shiromizu A; Kubo N; Kitano S
    Jpn J Clin Oncol; 2013 Mar; 43(3):321-3. PubMed ID: 23275647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case report of pathologically complete response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
    Miyazawa T; Ebe K; Fujita N; Koide N; Honma K; Ikarashi T
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):1001-3. PubMed ID: 22705702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
    Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C;
    Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
    Ueki T; Manabe T; Inoue S; Ienaga J; Yamanaka N; Egami T; Ishikawa M; Konomi H; Ikubo A; Nagayoshi K; Nakamura M; Tanaka M
    Anticancer Res; 2016 Feb; 36(2):741-7. PubMed ID: 26851033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
    Oba K; Matsuoka M; Satoh T; Muro K; Oriuchi N; Sakamoto J; Mishima H
    Jpn J Clin Oncol; 2011 Jan; 41(1):134-8. PubMed ID: 20819834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Schrag D; Weiser MR; Goodman KA; Gonen M; Hollywood E; Cercek A; Reidy-Lagunes DL; Gollub MJ; Shia J; Guillem JG; Temple LK; Paty PB; Saltz LB
    J Clin Oncol; 2014 Feb; 32(6):513-8. PubMed ID: 24419115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
    Park JH; Yoon SM; Yu CS; Kim JH; Kim TW; Kim JC
    Cancer; 2011 Aug; 117(16):3703-12. PubMed ID: 21328328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
    Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M;
    Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
    Créhange G; Bosset JF; Maingon P
    Cancer Radiother; 2011 Oct; 15(6-7):440-4. PubMed ID: 21802334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial.
    Xiao J; Chen Z; Li W; Yang Z; Huang Y; Zheng J; Deng Y; Wang L; Ren D; Peng J; Lan P; Wang J
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):21-7. PubMed ID: 25952796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
    Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.
    Caravatta L; Padula GD; Picardi V; Macchia G; Deodato F; Massaccesi M; Sofo L; Pacelli F; Rotondi F; Cecere G; Sallustio G; Di Lullo L; Piscopo A; Mignogna S; Bonomo P; Cellini N; Valentini V; Morganti AG
    Acta Oncol; 2011 Nov; 50(8):1151-7. PubMed ID: 21851185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy and rectal cancer].
    Michel P; Di Fiore F
    Cancer Radiother; 2011 Oct; 15(6-7):436-9. PubMed ID: 21885319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.